Log in to search using one of your social media accounts:

 

GSE108607 SUMOylation Regulates Transcription by the Progesterone Receptor A Isoform in a Target Gene Selective Manner

Contributors : Hany A Abdel-Hafiz ; Kate B HorwitzSeries Type : Expression profiling by arrayOrganism : Homo sapiensLuminal breast cancers express estrogen (ER) and progesterone (PR) receptors, and respond to endocrine therapies. However, some ER+PR+ tumors display intrinsic or acquired resistance, possibly related to PR. Two PR isoforms, PR-A and PR-B, regulate distinct gene subsets that may differentially influence tumor fate. A high PR-A:PR-B ratio is associated with poor prognosis and tamoxifen resistance. We speculate that excessive PR-A marks tumors that will relapse early. Here we address mechanisms by which PR-A regulate transcription, focusing on SUMOylation. We use receptor mutants and synthetic promoter/reporters to show that SUMOylation deficiency or the deSUMOylase SENP1 enhance transcription by PR-A, independent of the receptors ’ dimerization interface or DNA binding domain. De-SUMOylation exposes the agonist properties of the antiprogestin RU486. Thus, on synthetic promoters, SUMOylation functions as an independent brake on transcription by PR-A. What about PR-A SUMOylation of endogenous human breast cancer genes? To st udy these, we used gene expression profiling. Surprisingly, PR-A SUMOylation influences progestin target genes differentially, with some upregulated, others downregulated, and others unaffected. Hormone-independent gene regulation is also PR-A SUMOylation dependent. Several SUMOylated genes were ana lyzed in clinical breast cancer databas...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

Related Links:

Authors: Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumüller M, Guarducci C, Boccalini G, Gabellini S, Migliaccio I, Di Leo A, Pestrin M, Malorni L Abstract The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg) metastatic breast cancer (MBC) patients most likely to benefit from endocrine therapy (ET). We used the DiviTum™ assay to analyze TK1 activity in cell lysates of three HR+/HER2neg BC cell lines and in plasma of 31 HR+/H...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Breast cancer patients are at risk for alopecia with endocrine therapy, but hair growth can often be restored with topical minoxidil.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Opinion statementNeoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular bas...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Contributors : Jeff S Jasper ; Kimberly J Cocce ; Logan Everett ; Suzanne Wardell ; Thomas Westerling ; Taylor Krebs ; Robert Baldi ; Tricia M Wright ; Alex Yllanes ; Jeremy T Blitzer ; Craig Logsdon ; Daniel Rakiec ; David Ruddy ; Terry Hyslop ; Allison Hall ; Jeffrey R Marks ; Gregory E Crawford ; Myles Brown ; Donald P McdonnellSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen rec...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
A study, published inJAMA Dermatology, reports that endocrine therapy-induced alopecia in breast cancer patients is mechanistically similar to androgenetic alopecia.Medical Xpress
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
Conclusion BCS and ET without RT seem to be a safe treatment option in women ≥ 65 years with early breast cancer and favorable histopathology. The risk of IBTR is comparable to the risk of contralateral breast cancer. Moreover, concurrent morbidity dominates over breast cancer as leading cause of death in this cohort with low-risk breast tumors.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
92 percent had grade 1 severity alopecia with endocrine tx; pattern similar to androgenetic alopecia
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Dermatology, Gynecology, Oncology, Pharmacy, Journal, Source Type: news
THURSDAY, April 12, 2018 -- For patients with breast cancer, endocrine therapy-induced alopecia (EIA) has a pattern that is similar to androgenetic alopecia, according to a study published online April 11 in JAMA Dermatology. Azael Freites-Martinez,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Source: JAMA Dermatology - Category: Dermatology Source Type: research
This cohort study describes clinical features, quality of life, and response to minoxidil among female patients with breast cancer who have endocrine therapy –induced alopecia.
Source: JAMA Dermatology - Category: Dermatology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Endocrine Therapy | Genetics | Hormones | Tamoxifen